Veeva-Salesforce Split: An Overview for Life Sciences Organizations
The Veeva-Salesforce split has left many in the life sciences industry uncertain about migration, service agreements, and integrations.
It’s prompting them to reassess their technology options and consider the implications for their organizations.
Veeva will no longer sell its life sciences solution built on Salesforce.com (SFDC), and will offer its own proprietary CRM system, with existing Veeva customers having until 2030 to transition from Salesforce to the Veeva solution.
In this white paper, we look at:
- The split's implications for life sciences companies.
- How life sciences organizations can navigate the split.
- Reactions from the industry.
Download the white paper.
Trusted by
Vishal Dass
Vishal Dass is the VP of Healthcare & Life Sciences at Customertimes. He has more than 20 years of experience in the industry, both on the client and vendor side. Vishal uses his strong industry experience twinned with his background in biomedical engineering to leverage technology for increased HCP and patient engagement.
Reach out to him for a discovery call on how you can take your life sciences business to the next level.
/About Customertimes
Enabling companies to innovate, integrate, and transform
At Customertimes, we've been at the forefront of technology innovation for years, helping businesses across various industries transform and thrive. Our team of experts is dedicated to delivering comprehensive solutions tailored to your specific needs, leveraging the latest technologies and industry best practices.
